Philadelphia, PA, April 25, 2012 - The findings of a new study suggest that the protective effects of an active cognitive lifestyle arise through multiple biological pathways.
For some time researchers have been aware of a link between what we do with our brains and the long term risk for dementia. In general, those who are more mentally active or maintain an active cognitive lifestyle throughout their lives are at lower risk.
"The ideas of a 'brain reserve' or 'cognitive reserve' have been suggested to explain this, but were basically a black box. This research throws some light on what may be happening at the biological level," said Associate Professor Michael J. Valenzuela, a brain aging expert at the Brain and Mind Research Institute, University of Sydney, Australia, who led this new study.
Researchers used data from the Cognitive Function and Ageing Study, a large population-based study in the United Kingdom that has been following over 13,000 elderly individuals prospectively since 1991.
At the time of this study, 329 brains had been donated and were available for analysis. Brains were compared based on the individual's dementia status at death (yes or no) and cognitive lifestyle score, or CLS (low, middle, or high).
The three CLS groups did not differ among multiple Alzheimer's disease (AD) neuropathology measures, including plaques, neurofibrillary tangles, and atrophy. This means that cognitive lifestyle seems to have no effect on the brain changes typically seen in those with Alzheimer's disease.
However, an active cognitive lifestyle in men was associated with less cerebrovascular disease, in particular disease of the brain's microscopic blood vessels. An active cognitive lifestyle in women was associated with greater brain weight. In both men and women, high CLS was associated with greater neuronal density and cortical thickness in the frontal lobe.
"These findings suggest that increased engagement in stimulating activities are part of a lifestyle that is, overall, more healthy," commented Dr. John Krystal, Editor of Biological Psychiatry. "Rather than specifically protecting the health of activated circuits, it seems that a more active lifestyle has general effects on brain health reflected in greater neuronal density and preservation of the blood supply to the brain."
"Overall, our research suggests that multiple complex brain changes may be responsible for the 'use it or lose it' effect," Valenzuela added.
With a globally aging society and the risk of dementia increasing significantly with age, dementia-prevention strategies are of rising importance. Understanding the mechanisms of cognitive enhancement through research such as this can help support and inform the development of effective strategies to enrich cognitive lifestyle and potentially reduce dementia risk.
The article is "Multiple Biological Pathways Link Cognitive Lifestyle to Protection from Dementia" by Michael J. Valenzuela, Fiona E. Matthews, Carol Brayne, Paul Ince, Glenda Halliday, Jillian J. Kril, Marshall A. Dalton, Kathryn Richardson, Gill Forster, Perminder S. Sachdev, for the Medical Research Council Cognitive Function and Ageing Study (doi:10.1016/j.biopsych.2011.07.036). The article appears in Biological Psychiatry, Volume 71, Issue 9 (May 1, 2012), published by Elsevier.
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Associate Professor Michael J. Valenzuela at +61 2 9114 4135 or firstname.lastname@example.org.
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 4th out of 126 Psychiatry titles and 15th out of 237 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2010 Impact Factor score for Biological Psychiatry is 8.674.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Editorial Office, Biological Psychiatry
+1 214 648 0880